

Curriculum vitae

PERSONALIA

Navn: Sølvik, Una Ørvim

Nasjonalitet: Norsk

Fødselsdato: 28.09.1967

Sivilstatus: Gift

To barn, 18 og 21 år

UTDANNING

1992 – 1996 Ph.d. i Biologi, Biologisk Institutt, Universitetet i Oslo/ Nycomed Pharma AS, Oslo

1987 – 1991 Sivilingeniør (Kjemi), Norge Tekniske Høgskole, Kjemi-linjen, Trondheim

NÅVÆRENDE STILLING

2004 – Førsteamanuensis, Institutt for Global Helse og Samfunnsmedisin, Det medisinske fakultet, Universitetet i Bergen og Norsk kvalitetsforbedring av laboratorieundersøkelser (Noklus)

TIDLIGERE STILLINGER

1997 – 2001 Post doc, Immunologisk Institutt, Universitetet i Oslo og Rikshospitalet, Oslo

1997 Clinical research associate (CRA), Eli Lilly Norge AS, Oslo

1996 Post doc, Unité de Recherches sur l'Hémostase et la Thrombose, Hôpital de Bicêtre, National de la Santé et la Recherche Médical (INSERM), Le Kremlin Bicêtre, Frankrike

1992 Forsker, Axis Research AS, Oslo

VEILEDNING AV MASTERSTUDENTER OG Ph.d. KANDIDATER

Jeg har veiledet til sammen en Ph.d. kandidat, åtte masterstudenter, en medisinstudent og fire medisinstudenter til særoppgave. For tiden veileder jeg en Ph.d. kandidat og ti masterstudenter.

PÅGÅENDE SAMARBEIDSPROSJEKT

2015 – ”*Samples collection from healthy volunteers for Biological Variation Values Update*”, Internasjonalt samarbeidsprosjekt mellom syv laboratorier i seks ulike land. Ansvarlig for gjennomføringen i Norge.

2015 – “*Risk assessment of type 2 diabetes (T2D) in pharmacies*”, tre nasjonale samarbeidspartnere, ansvarlig for studien. Finansiert av Stiftelsen Til Fremme av Norsk Apotekfarmasi (ansvarlig for søknad om midler - 4 MNOK).

UNDERVISNING

2004 – Faglærer ved master i Helsevitenskap - forskningsmetode, Universitetet i Bergen

2004 – Sensor – master i Helsevitenskap - forskningsmetode, Universitetet i Bergen

2018 Sensor – master i Helsevitenskap - Masteroppgave, Universitetet i Bergen

2019 - Emneansvarlig Forskningsmetode (5 sp), Master i helse og samfunn, Universitetet i Bergen

2019 Sensor Forskningsmetode (5 sp), Master i helse og samfunn, Universitetet i Bergen

2019 Sensor Spesialpensum-rapport, Master i Helsevitenskap, Universitetet i Bergen

2020 - Emneansvarlig Kvantitative forskningsmetoder og tradisjoner (10 sp), Master i helse og samfunn, Universitetet i Bergen

PEDAGOGISKE KURS

- 2018 Workshop om pedagogiske mapper, Universitetet i Bergen
- 2017 Seminar om fokusgruppeintervju, Uni Research, Bergen
- 2016 Universitetspedagogikk, grunnmodul (10 sp), Det psykologiske fakultet, Universitetet i Bergen
- 2016 Seminar om utvalg og overførbarhet i kvalitative studier, Uni Research, Bergen
- 2016 Utdanningsprosjektet ved Institutt for global helse og samfunnsmedisin, UiB for 2016, ”Kollegabasert tilbakemelding – bruk av mitt UiB”
- 2015 Universitetspedagogikk, forskningsveiledning (5 sp), Det psykologiske fakultet, Universitetet i Bergen
- 2015 Seminar i forskningsveiledning for Ph.d.-veiledere, Det medisinske fakultet, Universitetet i Bergen
- 2015 Kurs i Team basert læring (TBL), Det Medisinske fakultet, Universitetet i Bergen
- 2015 Utdanningsprosjektet ved Institutt for global helse og samfunnsmedisin, UiB for 2015, ”Kollegabasert tilbakemelding”
- 2014 Universitetspedagogikk, muntlig formidling (5 sp), Det psykologiske fakultet, Universitetet i Bergen
- 2011 Seminar i forskningsveiledning for Ph.d.-veiledere, Det medisinske fakultet, Universitetet i Bergen

ANDRE KURS PÅ Ph.d. NIVÅ

- 2017 Analyse av registerdata i forskning, Institutt for klinisk medisin, UiT, Klinisk forskningsavdeling, UNN, Senter for klinisk dokumentasjon og evaluering (SKDE), Helse Nord, Tromsø 24.-26. April 2017
- 2009 Videregående statistikk via internett: Varians- og regresjonsanalyse, Legers etter- og videreutdanning, Universitetet i Oslo/Den norske legeforening.
- 2008 Videregående statistikk via internett: Tabellanalyse og logistisk regresjon, Legers etter- og videreutdanning, Universitetet i Oslo/Den norske legeforening.
- 2008 Innføring i statistikk via internett: Del II, Legers etter- og videreutdanning, Universitetet i Oslo/Den norske legeforening.
- 2007 Innføring i statistikk via internett: Del I, Legers etter- og videreutdanning, Universitetet i Oslo/Den norske legeforening.

INSTITUSJONELLE OPPGAVER

- 2019 – Leder av undervisningsgruppe i helsevitenskap, Institutt for Global Helse og Samfunnsmedisin, Det medisinske fakultet, Universitetet i Bergen
- 2019 Medlem av komite for midtveisevaluering av Ph.d. kandidat, Institutt for Global Helse og Samfunnsmedisin, Det medisinske fakultet, Universitetet i Bergen
- 2018 Leder av sakkyndig komité for vurdering av søkere til stilling som førsteamanuensis i allmennmedisin ved Institutt for global helse og samfunnsmedisin, Universitetet i Bergen.
- 2018 Leder (tredjeopponent) i en internasjonal bedømmelseskomité for doktorgradsavhandling ved Institutt for global helse og samfunnsmedisin, Universitetet i Bergen.
- 2017 Disputasleder, Institutt for global helse og samfunnsmedisin, Universitetet i Bergen
- 2016 – 2017 Leder for en komite som vurderte nivået på to emner for bioingeniører på masternivå ved Høgskolen på Vestlandet, oppnevnt av Det medisinske fakultet, Universitetet i Bergen.
- 2016 Disputasleder, Institutt for global helse og samfunnsmedisin, Universitetet i Bergen
- 2016 Leder (tredjeopponent) i en internasjonal bedømmelseskomité for doktorgradsavhandling ved Institutt for global helse og samfunnsmedisin, Universitetet i Bergen.
- 2015 Leder av sakkyndig komité for vurdering av søkere til stilling som Ph.d. ved Institutt for global helse og samfunnsmedisin, Universitetet i Bergen.
- 2015 Medlem for en sakkyndig komité for vurdering av søkere til stilling som Ph.d. ved Samfunnsfarmasi, Institutt for global helse og samfunnsmedisin, Universitetet i Bergen.
- 2012 – Ansvarlig for planlegging og organisering av forskningsmøter ved Noklus.
- 2011, 2015 Leder av Programutvalget for Master i Helsevitenskap, Institutt for global helse og

- samfunnsmedisin, Universitetet i Bergen.
- 2011, 2015 Medlem av Utvidet Studieleidelse for masterprogram ved Det medisinske fakultet, Universitetet i Bergen.
- 2011 – 2012 Leder for en komite som vurderte nivået på videreutdanninger for radiografer ved Høgskolen i Bergen, oppnevnt av Det medisinske fakultet, Universitetet i Bergen.
- 2011 – 2016 Medlem av fire ulike komiteer for midtveisevaluering av Ph.d. kandidater, Institutt for Global Helse og Samfunnsmedisin, Det medisinske fakultet, Universitetet i Bergen.
- 2011– Observatør i Samarbeidsorganet mellom Helse Vest RHF og høgskolene i regionen/Universitetet i Stavanger
- 2004 – Ansvarlig for master-studenter (radiografer og bioingeniører), Institutt for global helse og samfunnsmedisin, Universitetet i Bergen. 48 studenter er ferdige og 23 studenter er i løpet. Dette innebærer blant annet ansvar for opptak, planlegge og gjennomføre felles seminarer, veilede hvilke fagspesifikke emner studentene skal ta, veiledning og godkjenning av prosjektplan til masteroppgaven, skaffe sensorer til masteroppgaven og arrangere muntlig høring av masteroppgaven.
- 2004 – Medlem av Programutvalget for Master in Helsevitenskap, Institutt for global helse og samfunnsmedisin, Universitetet i Bergen.

MEDLEMSKAP I VITENSKAPELIGE FORENINGER

- 2015 – 2018 Korresponderende medlem, European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), Working Group on Congresses and Postgraduate Education (WG-CPE)
- 2015 – Medlem i Norsk Selskap for Medisinsk Biokjemi

REFEREE

Jeg har vært referee en eller flere ganger for følgende tidsskrift:

- Clinical Chemistry and Laboratory medicine (CCLM)
- Diabetology & Metabolic Syndrome
- Annals of Clinical Biochemistry
- Accreditation and Quality Assurance
- Norsk Farmaceutisk Tidsskrift
- PLoS ONE
- Journal of Diabetes Science and Technology
- The Scandinavian Journal of Clinical & Laboratory Investigation
- Journal of Clinical Laboratory Analysis
- BMC Infectious Diseases
- Journal of clinical laboratory analysis

KARRIERE OPPHOLD

01.09.1998 – 31.08.1999: Svangerskapspermisjon

01.01.2001 – 30.06.2003: Svangerskapspermisjon og opphold i Houston, USA

FULLSTENDIG PUBLIKASJONSLISTE

(byttet etternavn fra Ørvim til Sølvik 02.08.1997)

1. Risøy AJ, Kjome RLS, Sandberg S, **Sølvik UØ**. Diabetes risk assessments and HbA1c-measurements in Norwegian community pharmacies. Submitted BMJ Health Services Research
2. Kjome RL, Pettersen MS, Råheim M, **Sølvik UØ**. Being diagnosed with type 2 diabetes – shock, shame and information chaos. A focus group study among persons with type 2 diabetes in Norway. Submitted Scand J Primary Health Care.
3. **Sølvik UØ**, Løkkebø E, Kristoffersen AH, Brodin E, Averina M, Sandberg S. Quality of warfarin therapy and quality of life are improved by self-management for two years. *Thrombosis and Haemostasis* 2019;19:1632-1641. <https://www.thieme-connect.com/products/ejournals/html/10.1055/s-0039-1693703> .
4. Bukve T, Sandberg S, Wenche SV, **Sølvik U**, Christensen NG, Stavelin A. Commutability of a whole-blood external quality assurance material for point-of-care C-reactive protein, glucose, and hemoglobin testing. *Clin Chem* 2019;65:791-797. <http://clinchem.aaccjnls.org/content/clinchem/early/2019/03/06/clinchem.2018.300202.full.pdf>
5. Aarsand AK, Diaz-Garzon J, Fernandez-Calle P, Guerra E, Locatelli M, Bartlett WA, Sandberg S, Røraas T, Ceriotti F, **Sølvik UO**, Sylte MS, Coskun A, Serteser M, Unsal I, Tosato F, Plebani M, Jonker N, Barla G and Carobene A. The EuBIVAS: Within- and between-subject biological variation data for electrolytes, lipids, urea, uric acid, total protein, total bilirubin, direct bilirubin and glucose. *Clin Chem* 2018;64:9.
6. Gidske G, **Sølvik UØ**, Kristensen GB, Sandberg S. Hemolysis interference studies: Freeze Method should be used in the preparation of hemolyzed samples. *Clin Chem Lab Med*. 2018; 56:e220–e222.
7. **Sølvik UØ**, Risøy AJ, Kjome R, Sandberg S. Quality control of Norwegian Pharmacy HbA1c testing: A modest beginning. *J Diab Sci Technol*. 2018;12:753–761 <http://journals.sagepub.com/eprint/43MUKZ66cs8kvrKKFs2E/full>
8. Risøy AJ, Kjome RLS, Sandberg S, **Sølvik UØ**. Risk assessment and HbA1c measurement in Norwegian community pharmacies to identify people with undiagnosed type 2 diabetes - a feasibility study. *PLOS ONE*. 2018;13: e0191316. <https://doi.org/10.1371/journal.pone.0191316>.
9. Carobene A, Marino I, Coskun A, Serteser M, Unsal I, Guerra E, Bartlett WA, Sandberg S, Aarsand AK, Sylte MS, Røraas T, **Sølvik UO**, Fernandez-Calle P, Diaz-Garzon J, Tosato F, Plebani M, Jonker N, Barla G and Ceriotti F on behalf of the European Biological Variation Study of the EFLM Working Group on Biological Variation. The EuBIVAS Project: Within–and Between-Subject Biological Variation Data for Serum Creatinine Using Enzymatic and Alkaline Picrate Methods and Implications for Monitoring. *Clin Chem*. 2017;63. <http://clinchem.aaccjnls.org/content/early/2017/07/12/clinchem.2017.275115>
10. **Sølvik UØ**, Bjelkarøy WI, van den Berg K, Saga AL, Helle B, Hager HB and Sandberg S. Intensive educational efforts combined with external quality assessment improve the pre-analytical phase in general practitioner offices and nursing homes. *Clin Chem Lab Med*. 2017;55:1857-1864. DOI 10.1515/cclm-2016-1152

11. Carobene A, Røraas T, **Sølvik UO**, Sylte MS, Sandberg S, Guerra E, Marino I, Jonker N, Barla G, Bartlett WA, Fernandez-Calle P, Garzon JG, Tosato F, Plebani M, Coskun A, Serteser M, Unsal I, and Ceriotti F. Biological variation estimates obtained from 91 healthy subjects for nine enzymes in serum. On behalf of the European Biological Variation Study (EuBIVAS) of the EFLM working-group on biological variation. *Clin Chem* 2017;63:1141-1150.
12. Løkkebø EL, Kristoffersen AH, Stavelin A, **Sølvik UO**. Effect of dabigatran treatment at therapeutic levels on Point-of-Care International Normalized Ratio. *Clin Chem Lab Med* 2017; 55: e143–e145
13. Carobene A, Strollo M, Jonker N, Barla G, Bartlett WA, Sandberg S, Sylte MS, Røraas T, **Sølvik UO**, Fernandez-Calle P, Díaz-Garzón J, Tosato F, Plebani M, Coşkun A, Serteser M, Unsal I, Ceriotti F. Sample collections from healthy volunteers for biological variation estimates' update: a new project undertaken by the Working Group on Biological Variation established by the European Federation of Clinical Chemistry and Laboratory Medicine. *Clin Chem Lab Med* 2016;54:1599-608. doi: 10.1515/cclm-2016-0035.
14. Andreassen LM, Kjome RL, **Sølvik UO**, Houghton J, Desborough JA. The potential for deprescribing in care home residents with Type 2 diabetes. *Int J Clin Pharm* 2016;38:977-84.
15. Andreassen LM, Granås AG, **Sølvik UO**, Kjome RL. I try not to bother the residents too much' – a focus group study exploring the use of capillary blood glucose measurements in nursing homes. *BMC Nursing* 2016;15:7.
16. **Sølvik UO**, Risa M, Jacobsen C, Monsen G, Sandberg S. Performance of ten systems for self-monitoring of blood glucose by trained healthcare professionals and in the hands of the users. *Clin Chem* 2015;61:772-4.
17. **Sølvik UO**, Løkkebø ES, Kristoffersen AH, Stavelin A, Binder S, Sandberg S. Self-management of warfarin therapy. *Tidsskr Nor Legeforening* 2015;135:849-53.
18. Andreassen LM, Kjome RL, Kristensen G, **Sølvik UO**, Sandberg S. Nursing home patients with diabetes: Prevalence, drug treatment and glycemc control. *Diabetes Res Clin Pr* 2014;105:102-9.
19. **Sølvik UO**, Røraas TH, Petersen PH, Stavelin AV, Monsen G, Sandberg S. The influence of coagulation factors on the *in-treatment* biological variation of international normalized ratio for patients on warfarin. *Scand J Clin Lab Invest* 2014;74:470-6.
20. **Sølvik UO**, Røraas T, Christensen NG, Sandberg S. Diagnosing Diabetes Mellitus: Performance of Hemoglobin A_{1c} Point-of-Care Instruments in General Practice Offices. *Clin Chem* 2013;59:1790-801.
21. Stavelin A, Petersen PH, **Sølvik UO**, Sandberg S. External Quality Assessment of Point-of-Care Methods: Model for Combined Assessment of Method Bias and Single-Participant Performance by the Use of Native Patient Samples and Noncommutable Control Materials. *Clin Chem* 2013;59:363-71.
22. **Sølvik UO**, Røraas TH, Petersen PH, Stavelin AV, Monsen G, Sandberg S. Effect of coagulation factors on discrepancies in International Normalized Ratio results between instruments. *Clin Chem Lab Med* 2012;50:1611-20.
23. **Sølvik UO**, Petersen PH, Monsen G, Stavelin AV, Sandberg S. Discrepancies in international normalized ratio

- results between instruments: a model to split the variation into subcomponents. *Clin Chem* 2010;56:1618-26.
24. Stavelin A, Petersen PH, **Sølvi** U, Sandberg S. Internal quality control of prothrombin time in primary care: comparing the use of patient split samples with lyophilised control materials. *Thromb Haemost* 2009;102:593-600.
 25. **Sølvi** UØ, Stavelin A, Christensen NG, Sandberg S. External quality assessment of prothrombin time: the split-sample model compared with external quality assessment with commercial control material. *Scand J Clin Lab Invest* 2006;66:337-49.
 26. Orning L, Fischer PM, Hu CK, Agner E, Engebretsen M, Husbyn M, Petersen LB, **Ørvim** U, Llinas M, Sakariassen KS. A cyclic pentapeptide derived from the second EGF-like domain of Factor VII is an inhibitor of tissue factor dependent coagulation and thrombus formation. *Thromb Haemost* 2002;87:13-21.
 27. Saethre M, **Sølvi** UØ, Haraldsen G, Fiane AE, Boretti E, Thorsby E, Platt JL, Mollnes TE. Human serum-induced porcine endothelial cell E-selectin expression is associated with IgG3 and IgM anti-Gal antibodies. *Xenotransplantation* 2002;9:350-8.
 28. **Sølvi** UØ, Haraldsen G, Fiane AE, Boretti E, Lambris JD, Fung M, Thorsby E, Mollnes TE. Human serum-induced expression of E-selectin on porcine aortic endothelial cells in vitro is totally complement mediated. *Transplantation* 2001;72:1967-73.
 29. **Sølvi** UØ, Haraldsen G, Fiane AE, Boretti E, Thorsby E, Mollnes TE. C1-inhibitor attenuates human serum induced E-selectin expression of pig aortic endothelial cells. *Transplant Proc* 2001;33:789-90.
 30. Hagberg IA, **Sølvi** UØ, Opdahl H, Roald HE, Lyberg T. Inhalation of nitric oxide inhibits ADP-induced platelet aggregation and alpha-granule release. *Platelets* 1999;10:382-90.
 31. Sakariassen KS, Holme PA, **Ørvim** U, Barstad RM, Solum NO, Brosstad FR. Shear-induced platelet activation and platelet microparticle formation in native human blood. *Thromb Res* 1998;92(6 Suppl 2):S33-41.
 32. **Ørvim** U, Barstad RM, Orning L, Petersen LB, Ezban M, Hedner U, Sakariassen KS. Antithrombotic efficacy of inactivated active site recombinant factor VIIa is shear dependent in human blood. ***Arterioscler Thromb Vasc Biol*** 1997;17:3049-56.
 33. Holme PA, **Ørvim** U, Hamers MJ, Solum NO, Brosstad FR, Barstad RM, Sakariassen KS. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. ***Arterioscler Thromb Vasc Biol*** 1997;17:646-53.
 34. Barstad RM, Buchmann MS, Hamers MJ, Orning L, **Ørvim** U, Stormorken H, Sakariassen KS. Effects of ionic and nonionic contrast media on endothelium and on arterial thrombus formation. *Acta Radiol* 1996;37:954-61.
 35. **Ørvim** U, Barstad RM, Stormorken H, Brosstad F, Sakariassen KS. Immunologic quantification of fibrin deposition in thrombi formed in flowing native human blood. *Br J Haematol* 1996;95:389-98.
 36. Barstad RM, **Ørvim** U, Hamers MJ, Tjønnfjord GE, Brosstad FR, Sakariassen KS. Reduced effect of aspirin on thrombus formation at high shear and disturbed laminar blood flow. *Thromb Haemost* 1996;75:827-32.
 37. **Ørvim** U, Barstad RM, Vlasuk GP, Sakariassen KS. Effect of selective factor Xa inhibition on arterial thrombus

- formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis. **Arterioscler Thromb Vasc Biol** 1995;15:2188-94.
38. **Ørvim U**, Roald HE, Stephens RW, Roos N, Sakariassen KS. Tissue factor-induced coagulation triggers platelet thrombus formation as efficiently as fibrillar collagen at arterial blood flow conditions. **Arterioscler Thromb Vasc Biol** 1994;14:1976-83.
 39. Syversen PV, Saeter U, Cunha-Ribeiro L, **Ørvim U**, Sletten K, Husby G, Sakariassen KS. The effect of serum amyloid protein A fragment-SAA25-76 on blood platelet aggregation. *Thromb Res* 1994;76:299-305.
 40. Roald HE, **Ørvim U**, Bakken IJ, Barstad RM, Kierulf P, Sakariassen KS. Modulation of thrombotic responses in moderately stenosed arteries by cigarette smoking and aspirin ingestion. *Arterioscler Thromb* 1994;14:617-21.

Presentasjoner på kongresser, konferanser og symposium

1. Noklus national congress, Bodø, 28.-29. august 2018. Oral presentation: «Egenkontroll av Marevanbehandling - Resultater fra Helse Nord».
2. Vår møte Medisinsk biokjemi, Oslo, 3.-5. April 2017. Oral presentation: ”*Ekstern kvalitetssikring og målrettet undervisning forbedrer pre-analytisk kvalitet på legekantor og sykehjem*”.
3. The 48 national SIBIOC congress, Torino, Italy, October 18. – 20. 2016. Poster: Marino I, Carobene A, Guerra E, Jonker N, Barla G, Bartlett WA, Sandberg S, Sylte MS, Røraas T, **Sølvik UØ**, Fernandez-Calle P, Díaz-Garzón J, Tosato F, Plebani M, Coşkun A, Serteser M, Unsal I, Ceriotti F. “*Within and between-subject biological variation data obtained from 91 healthy subjects for serum creatinine using Enzymatic and Jaffe methods*”.
4. The 48 national SIBIOC congress, Torino, Italy, October 18. – 20. 2016. Poster: Marino I, Carobene A, Guerra E, Jonker N, Barla G, Bartlett WA, Sandberg S, Sylte MS, Røraas T, **Sølvik UØ**, Fernandez-Calle P, Díaz-Garzón J, Tosato F, Plebani M, Coşkun A, Serteser M, Unsal I, Ceriotti F. “*Within and between-subject biological variation data obtained from 91 healthy subjects for Total Cholesterol, HDL, LDL-Cholesterol and triglycerides in serum samples*”.
5. The 45th ESCP Annual Symposium ”Clinical pharmacy tackling inequalities and access to health care”, Oslo, Norway, 5. – 7. October 2016. Poster: Pettersen M, Kjome R, **Sølvik UØ**. “*It’s a jungle out there – a focus group study about being diagnosed with type 2 diabetes*”.
6. The 4th Joint EFLM-UEMS congress, Warszawa, Poland, 21. – 24. September 2016. Poster: **Sølvik UØ**, Bjelkarøy WI, van den Berg K, Saga AL, Hager HB, Sandberg S. “*Intensive educational efforts towards primary health care increase patient identification practice in blood sample collection and thereby patient safety*”.
7. The 4th Joint EFLM-UEMS congress, Warszawa, Poland, 21. – 24. September 2016. Poster: Marino I, Carobene A, Guerra E, Jonker N, Barla G, Bartlett WA, Sandberg S, Sylte MS, Røraas T, **Sølvik UØ**, Fernandez-Calle P, Díaz-Garzón J, Tosato F, Plebani M, Coşkun A, Serteser M, Unsal I, Ceriotti F. “*Within-subject biological variation data obtained from 91 healthy subjects for nine serum enzymes. Project of EFLM working-group on biological variation*”.
8. International Social Pharmacy Workshop, Aberdeen, Scotland, 19. – 22. July 2016. Poster: Risøy AJ, Kjome R, Sandberg S, **Sølvik UØ**. “*Risk assessment of type 2 diabetes in pharmacies*”.
9. The Norwegian Diabetes Association Research Conference, Oslo, Norway, 28. – 29. April 2016. Poster: Risøy AJ, Kjome R, Sandberg S, **Sølvik UØ**. “*Diabetesrisikotest i apotek*”.
10. EQALM symposium, Bergen, 8. – 9. October 2015. Poster: **Sølvik UØ**, Risa M, Jacobsen C, Monsen G, Sandberg S. “*Performance of ten systems for self-monitoring of blood glucose by trained healthcare professionals and in the hands of the users*”.
11. Siemens Point of Care Symposium, Middelfart, Denmark, 6. May 2015. Invited oral presentation: “*Bruk av POC-utstyr til diagnostikk av diabetes*”.
12. Nasjonalt Diabetesforum, Oslo, 22. – 23. April 2015. Oral presentation: “*HbA1c. Resultater fra ekstern kvalitetskontroll/Noklus*”.

13. Diabetes Technology Meeting, Maryland, USA, 6. – 8. November 2014. Poster: **Sølvik UØ**, Risa M, Jacobsen C, Monsen G, Sandberg S. “*Performance of systems for self-monitoring of blood glucose compared to the analytical quality specifications in ISO 15197:2013*”.
14. Noklus national congress, Stavanger, 9. – 10. September 2014.
Oral presentations: “*Egenkontroll av antikoagulasjonsbehandling*”
“*Egenmåling av glukose – blir instrumentene bedre?*”
15. Noklus national congress, Tromsø, 12. – 16. September 2013. Oral presentation: “*Klarer legekantor kvalitetskravene til diagnostikk av diabetes?*”.
16. EQALM Symposium, Herlev, Denmark, 25. - 26. October 2012. Oral presentation and poster: Stavelin A, Petersen PH, **Solvik UO**, Sandberg S. “*External quality assessment of point-of-care methods: Model for combined assessment of method bias and single participant performance by the use of native patient samples and non-commutable control materials*”.
17. Noklus national congress, Reykjavik, Island, 12. – 16. September 2012. Oral presentation: “*Analysekvalitet på HbA1c-instrumenter i allmennpraksis*”.
18. The 45th Nordic Coagulation Meeting, Stockholm, Sweden, 30. August – 1. September 2012.
Poster: **Sølvik UØ**, Røraas TH, Petersen PH, Stavelin AV, Monsen G, Sandberg S. “*In treatment biological variation of INR for patients on warfarin are reduced to the same level as for healthy individuals*”.
19. Norwegian National Advisory Unit on Learning and Mastery in Health national conference in patient and caregiver training, Oslo, 22. September 2011. Poster: Løkkebø ES, **Sølvik UØ**, Kristoffersen AH, Røraas T, Stavelin A, Sandberg S. “*Egenkontroll av antikoagulasjonsbehandling med warfarin blir bedre enn konvensjonell behandling etter grundig og strukturert opplæring*”.
20. The 23rd International Congress on Thrombosis and Hemostasis, Kyoto, Japan, 23. – 28. July 2011.
Poster: **Sølvik UØ**, Røraas TH, Petersen PH, Stavelin AV, Monsen G, Sandberg S. “*Discrepancies in International Normalized Ratio results between instruments; the effect of coagulation factors*”.
21. The 44th Nordic Coagulation Meeting, Aalborg, Denmark, 26. – 28. May 2011.
Poster: **Sølvik UØ**, Røraas TH, Petersen PH, Stavelin AV, Monsen G, Sandberg S. “*Discrepancies in International Normalized Ratio results between instruments; the effect of coagulation factors*”.
22. The 8th World congress on Health economics, Toronto 2011. Munkerud S, Løkkebø E, **Sølvik UØ**, Thue G, Sandberg S. Oral presentation: “*Cost – effectiveness of self-managed versus physician-managed oral anticoagulation therapy in Norway*”.
23. Noklus national congress, Bergen, 6. – 7. September, 2010.
Oral presentation: “*Årsaker til variasjon mellom POC PT-INR resultater og sykehusmetode*”.
24. The 43rd Nordic Coagulation Meeting, Helsinki, Finland, 26. – 28. August 2010.
Poster: **Sølvik UØ**, Petersen PH, Monsen G, Stavelin AV, Sandberg S. “*Discrepancies in Prothrombin Time International Normalized Ratio (PT-INR) results between instruments; a model to split the variation into different components*”.

25. The 32nd Nordic Congress in Medical Biochemistry, Oslo, Norway, 1. – 4. June 2010. Oral presentation: “*Discrepancies in Prothrombin Time International Normalized Ratio (PT-INR) results between instruments; the variation can be divided into different components*”.
26. The 32nd Nordic Congress in Medical Biochemistry, Oslo, Norway, 1. – 4. June 2010. Oral presentation: Stavelin A, Petersen PH, **Sølvik UØ**, Sandberg S. “*Internal quality control of prothrombin time in primary care: Comparing the use of patient split samples with lyophilized control materials*”.
27. Noklus national congress, Arendal, 15. – 16. September 2009. Oral presentation: “*Måling av PT-INR; avvik mellom instrumenter*”.
28. Noklus national congress, Haugesund, 23. – 24. September 2008. Oral presentation: “*Egenmåling av PT-INR – status*”.
29. Noklus congress, Lillestrøm, 13. – 14. February 2008. Oral presentation: “*Egenmåling av PT-INR, Noklus’ strategi*”.
30. The 16th IFCC-FESCC European Congress of Clinical Chemistry and Laboratory Medicine, Euromedlab, Glasgow, Scotland, 8. – 12. May 2005. Poster: **Sølvik UØ**, Stavelin A, Christensen NG, Sandberg S. “*External quality assessment of whole-blood prothrombin time: comparisons of two methods*”.
31. Congress in Transplantation, Roma, Italy August 2000. Oral presentation: “*Complement inhibition reduces human serum induced type II activation of porcine endothelial cells*”.
32. XVII International Complement Workshop, Rhodes, Greece, October 11-16 1998. Poster: **Sølvik UØ**, Mollnes TE, Fiane AE, Vartdal F, Endresen M, Thorsby E, Lambris JD. “*Inhibition of complement and xenogeneic endothelial cell activation by compstain*”. *Molecular Immunology*, 1998;35:372.
33. 40. Jahrestagung der Gesellschaft für Thrombose- und Hamostaseforschung, Interlaken, Germany, February 14-17 1996. Oral presentation: “*Inactivated active site recombinant FVIIa is an efficient FVIIa induced arterial thrombus formation in human blood*”.
34. 2nd FASEB Conference on Thrombin, Copper Mountain, Colorado, USA, August 13-18, 1995. Oral presentation: “*Flow conditions and thrombin*”.
35. XVth Congress of ISTH, Jerusalem, Israel, June 11-16, 1995. Oral presentation: **Ørvim U**, Barstad RM, Vlasuk GP, Sakariassen KS. “*Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/FVII and collagen in an ex vivo model on human shear dependent thrombogenesis*”. *Thromb Haemost* 1995;73:1086.
36. XVth Congress of ISTH, Jerusalem, Israel, June 11-16, 1995. Oral presentation: **Ørvim U**, Barstad RM, Orning L, Petersen LB, Ezban M, Hedner U, Sakariassen KS. “*Inactivated active site recombinant FVIIa is an efficient inhibitor of tissue factor/factor VIIa induced arterial thrombus formation in human blood*”. *Thromb Haemost* 1995;73:1085.
37. XVth Congress of ISTH, Jerusalem, Israel, June 11-16, 1995. Barstad RM, **Ørvim U**, Hamers MJAG, Roald HE, Tjønnfjord GE, Brosstad F, Sakariassen KS. *The geometry of arterial stenoses affects the beneficial effects of aspirin on collagen-induced thrombus formation*. *Thromb Haemost* 1995;73:1042.

38. ISTH, fortieth annual meeting of the scientific and standardization committee, "Rheology and biomaterials", Leuven, Belgium, September 18-19, 1994. Oral presentation: "*New directions for use of ex vivo flow systems: evaluation of novel antithrombotic drugs*".
39. Oslo Vascular Biology Club, Oslo, December 14, 1993. Oral presentation: "*Development and characterization of an infusion and mixing device for test agents in flowing native blood of the human models of ex vivo thrombogenesis: effects of recombinant Tick Anticoagulant Peptide on TF/FVII dependent thrombus formation,*"
40. Oslo Vascular Biology Club, Oslo, September 15, 1993. Oral presentation: "*Development and characterization of a new tissue factor surface for induction of human thrombogenesis at venous and arterial blood flow conditions*".
41. XIVth ISTH Congress & 39th Annual SSC Meeting, New York City (NY), USA, July 4-9, 1993. Roald HE, **Ørvim U**, Barstad RM, Bakken IJ, Kierulf P, Westvik AB, Sakariassen KS. *Smokers have an increased thrombotic response at high arterial shear rates, which can be reduced by aspirin ingestion*. Thromb Haemost 1993;69:796.

Mediaoppslag:

28.06.2010: Dagens Medisin om egenmåling av PT-INR

(<http://www.dagensmedisin.no/nyheter/2010/06/28/bedre-med-egenmaling-av-in/index.xml>)